Observational electronic medical record data on >840K women with breast cancer indicates use of a GLP-1 agonist is associated with half the rate of recurrence or death compared with nonuse or with insulin/metformin, with authors pointing toward both indirect metabolic effects and even potential direct antitumor activity. | Tatum, JAMA Netw Open 2026
